At IgGenix, our mission is to develop a first-in-class therapy for millions of people whose daily lives are limited by food allergies and other severe allergic conditions. Starting from a deep understanding of molecular immunology, we employ an antibody-based therapeutic platform to potentially enable faster, deeper and more sustained clinical responses. We push the limits of single-cell genomic technology to capture and analyze very rare human B cells expressing allergen binding antibodies and then engineer these antibodies to uniquely capture allergens and endow them with powerful immune modulating activities derived from the IgG antibody class to suppress allergic reactions. Our team is at work today to make this new life changing therapy tomorrow’s reality.

The End of Food Allergy

Available Now

Our daughter’s world changed dramatically after Dr. Nadeau successfully treated her life‑threatening food allergy. If you suffer from food allergy, or have a loved one who does, this book is a must-read!

Nancy and Steve Carell

The End of Food Allergy…provides hope for treatments that may liberate many children and adults suffering from this epidemic. I am grateful…

Sheryl Sandberg

As a mother of children with a history of food allergy, I am grateful for the hope that this book gives families: that we no longer have to live their lives in fear of accidental exposure. Thank you for changing our world.

Priscilla Chan, MD

Share this post

Join our email community for News, Updates, and Insights